BioSpace News Archive

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a reduction in workforce of approximately 30% of its head count to focus on development of its first-in-class PDK1 inhibitor SNS-510.

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that it has appointed biopharmaceutical industry veteran Thomas M. Soloway to its Board of Directors effective July 2, 2020.

Aeterna Zentaris Inc., a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, announced the closing of its previously announced public offering of 17,544,516 units at a price to the public of $0.45 per unit and 9,122,150 pre-funded units at a price to the public of $0.4499 per pre-funded unit.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company pioneering targeted C3 therapies, announced that the company approved the grant of equity awards to three new employees with a grant date of July 1, 2020, as an equity inducement award outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Astex Pharmaceuticals, Inc.; Taiho Oncology, Inc.; and Otsuka Pharmaceutical Co., Ltd. today announce that the U.S. Food and Drug Administration (FDA) and Health Canada have approved INQOVI® (decitabine and cedazuridine) tablets

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced the pricing of its previously announced underwritten public offering of 7,142,857 shares of its common stock at a price to the public of $42.00 per share.

Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced the pricing of its underwritten public offering of 4,225,352 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $142.00 per ADS.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

The U.S. Food and Drug Administration authorized the marketing of Philip Morris Products S.A.'s “IQOS Tobacco Heating System” as modified risk tobacco products.

The unprecedented emergency authorization of remdesivir for treating COVID-19 only four months after the virus was discovered was enabled by decades of basic research on the drug’s biological target and drugs with similar parent structures, and was supported by $6.5 billion in NIH funding, according to a study from Bentley University